Elan holders OK buyback, vote down three deals (Update)

Shareholders of Irish drugmaker Elan Corp. PLC have potentially ended a takeover bid from Royalty Pharma by voting in favor of an Elan share buyback plan.

The Dublin-based company's shareholders also rejected at a Monday meeting three separate deals that the Elan board has pushed instead of the Royalty takeover bid.

Earlier this month, New York-based Royalty offered to pay $13 per share for each Elan share plus up to $2.50 per share in payments based on performance milestones. That totaled about $7.76 billion not counting the milestone payments.

An Irish Takeover Panel requires Royalty to withdraw its offer if shareholders approved the buyback or the acquisitions. Royalty is challenging that requirement in court.

Royalty Pharma said Monday that Elan shareholders can continue to accept its latest bid while the court challenge is pending. The Irish High Court will hold a hearing Wednesday on the case.

Elan was attempting to diversify its business through the string of acquisitions after it sold its interest in the multiple sclerosis treatment Tysabri to former development partner Biogen Idec Inc. earlier this year. That deal was worth $3.25 billion in cash and recurring royalty payments.

The acquisitions included purchasing a share of the royalties for four drugs from Theravance Inc., as well as acquiring Austrian drug developer AOP Orphan. Elan said last week it would explore selling the company after it became clear that shareholders would reject the acquisitions.

Elan also said Royalty could participate in its formal sale process, but it urged shareholders to steer clear of Royalty's latest bid.

Royalty is a privately held company that buys drug royalty interests. It has made several bids this year to buy Elan.

U.S.-traded shares of Elan fell 10 cents to $13.56 Monday in midday trading, while the Standard & Poor's 500 index climbed about 1 percent.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Judge halts Royalty Pharma's bid for Elan stock

Jun 04, 2013

Irish drugmaker Elan Corp.'s fight against a takeover bid by Royalty Pharma has spilled into U.S. federal court, where a judge has issued a temporary restraining order preventing Royalty from completing its offer to buy the ...

Recommended for you

Is head CT overused in emergency departments?

2 hours ago

Less than 7.1% of patients presenting to the emergency department with dizziness and 6.4% complaining of syncope or near-syncope benefited from head CT say researchers at Kaiser Foundation Hospital in Honolulu. The use of ...

Medical radiation may be reduced to one-sixth

4 hours ago

One of this century's most significant mathematical discoveries may reduce the number of measuring points to one-sixth of the present level. This means reduced exposure to radiation and faster medical imaging ...

The 'fifth taste,' umami, could be beneficial for health

17 hours ago

The umami taste could have an important and beneficial role in health, according to research published in the open access journal Flavour. The journal's special series of articles 'The Science of Taste' also finds that ' ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.